

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4896264

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GENENCOR INTERNATIONAL B V	03/26/2018
RECEIVING PARTY DATA	
Name:	E I DU PONT DE NEMOURS AND COMPANY
Street Address:	974 CENTRE ROAD, P O BOX 2915
Internal Address:	CHESTNUT RUN PLAZA 721
City:	WILMINGTON
State/Country:	DELAWARE
Postal Code:	19805
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15702893
CORRESPONDENCE DATA	
Fax Number:	(302)355-1464
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3029996357
Email:	Patricia.T.Panariello@dupont.com
Correspondent Name:	PATRICIA TURNER PANARIELLO
Address Line 1:	974 CENTRE ROAD, P O BOX 2915
Address Line 2:	CHESTNUT RUN PLAZA 721/2311
Address Line 4:	WILMINGTON, DELAWARE 19805
ATTORNEY DOCKET NUMBER:	CL6395USNP
NAME OF SUBMITTER:	PATRICIA TURNER PANARIELLO
SIGNATURE:	/Patricia Turner Panariello/
DATE SIGNED:	04/03/2018
Total Attachments: 1	
source=CL6395USNP_Assignment_GenencorIntIBVInventors_SIGNED#page1.tif	

NON-PROVISIONAL APPLICATION ASSIGNMENT

We, the undersigned

SLAVKO KRALJ, VELI ALKAN

Hereby declare that

We are the inventors of an invention entitled


ENGINEERED GLUCOSYLTRANSFERASES

which is disclosed in the United States Patent Application No. 15/702893 filed on September 13, 2017 and which is identified as Case Number CL6395-US-NP.


For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our pre-existing obligation of assignment, we hereby:

I. Sell, assign, and transfer unto GENECOR INTERNATIONAL B.V., a corporation organized and existing under the laws of The Netherlands and having its principal place of business at Archimedesweg 30, 2333 CN, The Netherlands, hereinafter referred to as the assignee, (A) the entire right, title, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of the International Convention for the Protection of Industrial Property and any other treaty or understanding for intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all inventions, whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and

II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives, any facts known to us respecting said inventions or the rights described above, to testify in any legal proceeding respecting said inventions or the rights described above, the location of that testimony to be in the country in which we reside or in the nearest country in which such testimony is legal should our country of residence prohibit such testimony, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions.


_____(L.S.)
SLAVKO KRALJ

DATE: 13 MARCH 2018


_____(L.S.)
VELI ALKAN

DATE: March 13, 2018